Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.93), $0.76 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.75 million versus the consensus estimate of $2.33 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.